SCHEMBL4919985

SCHEMBL4919985

Cc1nc(Sc2ccccc2)sc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 1/20 0.49
RAB9A P51151 5/20 0.46
GAA P10253 1/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 1/20 0.46
NPC1 O15118 3/20 0.46
MAPT P10636 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
POLB P06746 2/20 0.44
TDP1 Q9NUW8 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RECQL P46063 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28040340 0.86 SMN1; SMN2 (0.44) SMN1; SMN2KDM4EKMT2ARAB9AGAA
SCHEMBL4493748 0.83 ALDH1A1 (0.58) SMN1; SMN2KDM4EKMT2ARAB9AALDH1A1
SCHEMBL11589506 0.77 POLB (0.44) SMN1; SMN2KMT2AALDH1A1HPGDMAPT
SCHEMBL4481950 0.77 PTGDR2 (0.42) SMN1; SMN2KDM4EKMT2AGAAALDH1A1
SCHEMBL10360761 0.77 ALDH1A1 (0.57) SMN1; SMN2KDM4EKMT2ARAB9AGAA
SCHEMBL11586890 0.76 PPARG (0.42) SMN1; SMN2GAAALDH1A1HPGDMAPT
SCHEMBL8177039 0.75 ALDH1A1 (0.52) SMN1; SMN2KDM4EKMT2AGAAALDH1A1
SCHEMBL4480982 0.74 TDP1 (0.48) SMN1; SMN2GAAALDH1A1TSHRMAPT
SCHEMBL4765587 0.74 RAB9A (0.41) SMN1; SMN2KDM4EKMT2ARAB9AGAA
SCHEMBL4477996 0.72 TDP1 (0.40) SMN1; SMN2GAAALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US claimed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP claimed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO claimed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed
US-4077968-A ANTIINFLAMMATORY, ANTIRHEUMATIC, ANALGESIC, ANTILIPEMIC SHIONOGI & CO., LTD. (JA) 1978-03-07 US disclosed
US-4025528-A ANTIINFLAMMATORY, ANALGESIC, ANTILIPEMIC SHIONOGI & CO., LTD. (JA) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 SMN1; SMN2 2251/4885KDM4E 1589/4885KMT2A 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.